209 related articles for article (PubMed ID: 33470063)
21. Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.
Li N; Zhu J; Yin R; Wang J; Pan L; Kong B; Zheng H; Liu J; Wu X; Wang L; Huang Y; Wang K; Zou D; Zhao H; Wang C; Lu W; Lin A; Lou G; Li G; Qu P; Yang H; Zhang Y; Cai H; Pan Y; Hao M; Liu Z; Cui H; Yang Y; Yao S; Zhen X; Hang W; Hou J; Wang J; Wu L
JAMA Oncol; 2023 Sep; 9(9):1230-1237. PubMed ID: 37440217
[TBL] [Abstract][Full Text] [Related]
22. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
[TBL] [Abstract][Full Text] [Related]
23. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
Mirza MR; Bergmann TK; Mau-Sørensen M; Christensen RD; Åvall-Lundqvist E; Birrer MJ; Jørgensen M; Roed H; Malander S; Nielsen F; Lassen U; Brøsen K; Bjørge L; Mäenpää J
Cancer Chemother Pharmacol; 2019 Oct; 84(4):791-798. PubMed ID: 31375879
[TBL] [Abstract][Full Text] [Related]
24. Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study.
Gallagher JR; Heap KJ; Carroll S; Travers K; Harrow B; Westin SN
Future Oncol; 2019 Dec; 15(36):4197-4206. PubMed ID: 31707856
[No Abstract] [Full Text] [Related]
25. Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
Ai X; Pan Y; Shi J; Yang N; Liu C; Zhou J; Zhang X; Dong X; He J; Li X; Chen G; Li X; Zhang H; Liao W; Zhang Y; Ma Z; Jiang L; Cui J; Hu C; Wang W; Huang C; Zhao J; Ding C; Hu X; Wang K; Gao B; Song Y; Liu X; Xiong J; Liu A; Li J; Liu Z; Li Y; Wang M; Zhang B; Zhang D; Lu S
J Thorac Oncol; 2021 Aug; 16(8):1403-1414. PubMed ID: 33915252
[TBL] [Abstract][Full Text] [Related]
26. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
González-Martín A; Pothuri B; Vergote I; Graybill W; Lorusso D; McCormick CC; Freyer G; Backes F; Heitz F; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Malinowska IA; Shtessel L; Compton N; Mirza MR; Monk BJ
Eur J Cancer; 2023 Aug; 189():112908. PubMed ID: 37263896
[TBL] [Abstract][Full Text] [Related]
27. The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.
Ni J; Cheng X; Zhao Q; Dai Z; Xu X; Guo W; Gu H; Zhou R; Wang Y; Chen X
J Ovarian Res; 2021 May; 14(1):68. PubMed ID: 33993885
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China.
Zhao M; Qiu S; Wu X; Miao P; Jiang Z; Zhu T; Xu X; Zhu Y; Zhang B; Yuan D; Zhang Y; Sun W; He A; Zhao M; Hou W; Zhang Y; Shao Z; Jia M; Li M; Chen J; Xu J; Chen B; Zhou Y; Shen Y
Target Oncol; 2023 Nov; 18(6):869-883. PubMed ID: 37847485
[TBL] [Abstract][Full Text] [Related]
29. Phase I Pharmacokinetic Study of Niraparib in Chinese Patients with Epithelial Ovarian Cancer.
Zhang J; Zheng H; Gao Y; Lou G; Yin R; Ji D; Li W; Wang W; Xia B; Wang D; Hou J; Yan J; Hei Y; Zhang ZY; Milton A; Wu X
Oncologist; 2020 Jan; 25(1):19-e10. PubMed ID: 31439812
[TBL] [Abstract][Full Text] [Related]
30. Niraparib: A Review in Ovarian Cancer.
Heo YA; Duggan ST
Target Oncol; 2018 Aug; 13(4):533-539. PubMed ID: 30073633
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
Musacchio L; Salutari V; Pignata S; Braicu E; Cibula D; Colombo N; Frenel JS; Zagouri F; Carbone V; Ghizzoni V; Giolitto S; Giudice E; Perri MT; Ricci C; Scambia G; Lorusso D
Int J Gynecol Cancer; 2021 Oct; 31(10):1369-1373. PubMed ID: 34607820
[TBL] [Abstract][Full Text] [Related]
32. Increase in creatinine levels associated with niraparib maintenance therapy in ovarian cancer.
Takahashi Y; Taguchi M; Tamura K; Shinohara M; Koyanagi T; Takahashi S; Taneichi A; Takei Y; Saga Y; Fujiwara H
J Obstet Gynaecol Res; 2024 Mar; 50(3):501-507. PubMed ID: 38115203
[TBL] [Abstract][Full Text] [Related]
33. The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study.
Yonemori K; Shimizu T; Kondo S; Iwasa S; Koyama T; Kitano S; Sato J; Shimomura A; Shibaki R; Suri A; Kase Y; Sumino S; Tamura K; Yamamoto N
Jpn J Clin Oncol; 2021 Apr; 51(5):693-699. PubMed ID: 33621324
[TBL] [Abstract][Full Text] [Related]
34. Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer.
Vilming B; Fallås Dahl J; Bentzen AG; Ingebrigtsen VA; Berge Nilsen E; Vistad I; Dørum A; Solheim O; Bjørge L; Zucknick M; Aune G; Lindemann K
Int J Gynecol Cancer; 2023 Dec; 33(12):1898-1905. PubMed ID: 38000795
[TBL] [Abstract][Full Text] [Related]
35. Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Lee A
Target Oncol; 2021 Nov; 16(6):839-845. PubMed ID: 34635996
[TBL] [Abstract][Full Text] [Related]
36. Niraparib - A promising drug with hematological toxicity.
Patibandla NS; Monga DK
J Oncol Pharm Pract; 2019 Oct; 25(7):1749-1753. PubMed ID: 30293481
[TBL] [Abstract][Full Text] [Related]
37. Niraparib: First Global Approval.
Scott LJ
Drugs; 2017 Jun; 77(9):1029-1034. PubMed ID: 28474297
[TBL] [Abstract][Full Text] [Related]
38. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon TW; Tamura K; Sonke GS; Lisyanskaya A; Kim JH; Filho EA; Milenkova T; Lowe ES; Rowe P; Vergote I; Pujade-Lauraine E;
Lancet Oncol; 2021 May; 22(5):620-631. PubMed ID: 33743851
[TBL] [Abstract][Full Text] [Related]
39. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Wu L; Zhong L
J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
[TBL] [Abstract][Full Text] [Related]
40. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]